Vasoactive Peptides in Portal Pressure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Bayside Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00163982
First received: September 13, 2005
Last updated: July 25, 2007
Last verified: September 2005
  Purpose

This study is looking at the detection of vasoactive peptides in portal hypertension.


Condition Intervention
Portal Hypertension
Drug: Norfloxacin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Bayside Health:

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • HVPG >= 12 mmHg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163982

Contacts
Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au

Locations
Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3181
Contact: William W Kemp, MBBS, FRACP    92762000 ext 3327    w.kemp@alfred.org.au   
Sponsors and Collaborators
Bayside Health
Investigators
Principal Investigator: William W Kemp, MBBS, FRACP The Alfred
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00163982     History of Changes
Other Study ID Numbers: AH4204
Study First Received: September 13, 2005
Last Updated: July 25, 2007
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:
HVPG > 12 mmHg

Additional relevant MeSH terms:
Hypertension
Hypertension, Portal
Vascular Diseases
Cardiovascular Diseases
Liver Diseases
Digestive System Diseases
Norfloxacin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 28, 2014